

Tsanyang Jake Liang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9013963/publications.pdf>

Version: 2024-02-01

109
papers

14,632
citations

23544

58
h-index

24961

109
g-index

112
all docs

112
docs citations

112
times ranked

14288
citing authors

#	ARTICLE	IF	CITATIONS
1	Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. <i>Nature Medicine</i> , 2005, 11, 791-796.	15.2	2,561
2	Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. <i>Science</i> , 2014, 343, 1221-1228.	6.0	774
3	Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C. <i>Annals of Internal Medicine</i> , 2000, 132, 296.	2.0	764
4	A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. <i>Hepatology</i> , 2004, 39, 188-196.	3.6	679
5	Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. <i>Gastroenterology</i> , 2017, 152, 1297-1309.	0.6	442
6	Current and Future Therapies for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1907-1917.	13.9	418
7	Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy. <i>Annals of Internal Medicine</i> , 2008, 148, 519.	2.0	407
8	The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 52, 894-903.	3.6	403
9	Progression of fibrosis in chronic hepatitis C. <i>Gastroenterology</i> , 2003, 124, 97-104.	0.6	368
10	Hepatitis C Virus Structural Proteins Assemble into Viruslike Particles in Insect Cells. <i>Journal of Virology</i> , 1998, 72, 3827-3836.	1.5	345
11	A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 545-558.	3.7	342
12	A genome-wide genetic screen for host factors required for hepatitis C virus propagation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 16410-16415.	3.3	333
13	Present and future therapies of hepatitis B: From discovery to cure. <i>Hepatology</i> , 2015, 62, 1893-1908.	3.6	269
14	Natural Killer Cells Are Polarized Toward Cytotoxicity in Chronic Hepatitis C in an Interferon- α -Dependent Manner. <i>Gastroenterology</i> , 2010, 138, 325-335.e2.	0.6	243
15	Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. <i>Hepatology</i> , 2007, 46, 1548-1563.	3.6	242
16	HCV Infection Induces a Unique Hepatic Innate Immune Response Associated With Robust Production of Type III Interferons. <i>Gastroenterology</i> , 2012, 142, 978-988.	0.6	241
17	Pathogenesis of hepatitis C-associated hepatocellular carcinoma. <i>Gastroenterology</i> , 2004, 127, S62-S71.	0.6	203
18	β -Hydroxysteroid Dehydrogenase 13 is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 1504-1519.	3.6	200

#	ARTICLE	IF	CITATIONS
19	Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. <i>Nature Medicine</i> , 2012, 18, 1060-1068.	15.2	198
20	Hepatitis C virus infection activates an innate pathway involving IKK- λ in lipogenesis and viral assembly. <i>Nature Medicine</i> , 2013, 19, 722-729.	15.2	167
21	Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 8427-8432.	3.3	157
22	Is SARS-CoV-2 Also an Enteric Pathogen With Potential Fecal-Oral Transmission? A COVID-19 Virological and Clinical Review. <i>Gastroenterology</i> , 2020, 159, 53-61.	0.6	157
23	Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 6753-6758.	3.3	152
24	Current progress in development of hepatitis C virus vaccines. <i>Nature Medicine</i> , 2013, 19, 869-878.	15.2	144
25	Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. <i>Hepatology</i> , 2011, 53, 32-41.	3.6	140
26	Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model. <i>Journal of Clinical Investigation</i> , 2014, 124, 4953-4964.	3.9	131
27	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: Table 1. <i>Gut</i> , 2015, 64, 1824-1833.	6.1	128
28	Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages. <i>Hepatology</i> , 2017, 66, 1779-1793.	3.6	128
29	Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. <i>Gastroenterology</i> , 2003, 124, 352-360.	0.6	124
30	Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. <i>Science Translational Medicine</i> , 2015, 7, 282ra49.	5.8	118
31	Interaction of Hepatitis C Virus-Like Particles and Cells: a Model System for Studying Viral Binding and Entry. <i>Journal of Virology</i> , 2002, 76, 9335-9344.	1.5	113
32	The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C. <i>Antiviral Chemistry and Chemotherapy</i> , 2012, 23, 1-12.	0.3	109
33	Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling. <i>Gastroenterology</i> , 2010, 139, 154-162.e4.	0.6	108
34	Immunization with Hepatitis C Virus-Like Particles Induces Humoral and Cellular Immune Responses in Nonhuman Primates. <i>Journal of Virology</i> , 2004, 78, 6995-7003.	1.5	106
35	Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions. <i>Journal of Hepatology</i> , 2017, 66, 494-503.	1.8	105
36	An in vitro model of hepatitis C virion production. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2579-2583.	3.3	104

#	ARTICLE	IF	CITATIONS
37	Therapy of Hepatitis C “ Back to the Future. <i>New England Journal of Medicine</i> , 2014, 370, 2043-2047.	13.9	102
38	Integrative Functional Genomics of Hepatitis C Virus Infection Identifies Host Dependencies in Complete Viral Replication Cycle. <i>PLoS Pathogens</i> , 2014, 10, e1004163.	2.1	101
39	Direct, Interferon-Independent Activation of the CXCL10 Promoter by NF- κ B and Interferon Regulatory Factor 3 during Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2014, 88, 1582-1590.	1.5	96
40	Production of Infectious Hepatitis C Virus of Various Genotypes in Cell Cultures. <i>Journal of Virology</i> , 2007, 81, 4405-4411.	1.5	95
41	Hepatitis C virus“like particles induce virus-specific humoral and cellular immune responses in mice. <i>Hepatology</i> , 2001, 34, 417-423.	3.6	90
42	Inhibition of Cellular Proteasome Activities Enhances Hepadnavirus Replication in an HBX-Dependent Manner. <i>Journal of Virology</i> , 2004, 78, 4566-4572.	1.5	90
43	Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection. <i>Gastroenterology</i> , 2019, 156, 311-324.	0.6	85
44	Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. <i>Hepatology</i> , 2003, 38, 66-74.	3.6	83
45	Hepatitis C “ identifying patients with progressive liver injury. <i>Hepatology</i> , 2006, 43, S194-S206.	3.6	82
46	Scavenger Receptor Class B Is Required for Hepatitis C Virus Uptake and Cross-Presentation by Human Dendritic Cells. <i>Journal of Virology</i> , 2008, 82, 3466-3479.	1.5	79
47	Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry. <i>Gastroenterology</i> , 2009, 137, 673-681.	0.6	78
48	Reactivation of Hepatitis B During Immunosuppressive Therapy: Potentially Fatal Yet Preventable. <i>Annals of Internal Medicine</i> , 2012, 156, 743.	2.0	74
49	Hepatic differentiation of human pluripotent stem cells in miniaturized format suitable for high-throughput screen. <i>Stem Cell Research</i> , 2016, 16, 640-650.	0.3	74
50	Antibodies Against Hepatitis C Virus“Like Particles and Viral Clearance in Acute and Chronic Hepatitis C. <i>Hepatology</i> , 2000, 32, 610-617.	3.6	72
51	Structural Features of Envelope Proteins on Hepatitis C Virus-like Particles as Determined by Anti-envelope Monoclonal Antibodies and CD81 Binding. <i>Virology</i> , 2002, 298, 124-132.	1.1	71
52	Inhibition of Hepatitis C Virus-Like Particle Binding to Target Cells by Antiviral Antibodies in Acute and Chronic Hepatitis C. <i>Journal of Virology</i> , 2004, 78, 9030-9040.	1.5	70
53	Experimental models of hepatitis B and C “ new insights and progress. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 362-374.	8.2	70
54	Cellular microRNA networks regulate host dependency of hepatitis C virus infection. <i>Nature Communications</i> , 2017, 8, 1789.	5.8	70

#	ARTICLE	IF	CITATIONS
55	Vaccine Development for Hepatitis C. <i>Seminars in Liver Disease</i> , 2000, 20, 211-226.	1.8	67
56	Dynamic Interaction of Stress Granules, DDX3X, and IKK- β Mediates Multiple Functions in Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2015, 89, 5462-5477.	1.5	67
57	Src Homology 3 Domain of Hepatitis C Virus NS5A Protein Interacts With Bin1 and Is Important for Apoptosis and Infectivity. <i>Gastroenterology</i> , 2006, 130, 794-809.	0.6	62
58	Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. <i>Hepatology</i> , 2008, 48, 732-740.	3.6	56
59	Induction of Sterilizing Immunity against West Nile Virus (WNV), by Immunization with WNV-like Particles Produced in Insect Cells. <i>Journal of Infectious Diseases</i> , 2004, 190, 2104-2108.	1.9	51
60	Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. <i>Virology</i> , 2007, 367, 126-134.	1.1	51
61	Mouse models for the study of HCV infection and virus-host interactions. <i>Journal of Hepatology</i> , 2008, 49, 134-142.	1.8	51
62	Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. <i>Gut</i> , 2014, 63, 161-169.	6.1	51
63	Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 7620-7625.	3.3	50
64	Combination Therapy for Hepatitis C Infection. <i>New England Journal of Medicine</i> , 1998, 339, 1549-1550.	13.9	48
65	Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. <i>Hepatology</i> , 2003, 37, 52-59.	3.6	48
66	Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7. <i>Gastroenterology</i> , 2017, 152, 257-270.e7.	0.6	43
67	Hepatitis B Virus Deregulates the Cell Cycle To Promote Viral Replication and a Premalignant Phenotype. <i>Journal of Virology</i> , 2018, 92, .	1.5	43
68	What is the future of ribavirin therapy for hepatitis C?. <i>Antiviral Research</i> , 2014, 104, 34-39.	1.9	41
69	Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy. <i>Hepatology</i> , 2018, 68, 2078-2088.	3.6	38
70	Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. <i>Journal of Clinical Investigation</i> , 2020, 130, 3205-3220.	3.9	38
71	Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. <i>Hepatology</i> , 2011, 54, 1135-1148.	3.6	37
72	Novel Function of CD81 in Controlling Hepatitis C Virus Replication. <i>Journal of Virology</i> , 2010, 84, 3396-3407.	1.5	35

#	ARTICLE	IF	CITATIONS
73	Hepatitis B Surface Antigen Activates Unfolded Protein Response in Forming Ground Glass Hepatocytes of Chronic Hepatitis B. <i>Viruses</i> , 2019, 11, 386.	1.5	35
74	Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells. <i>Hepatology</i> , 2021, 74, 2998-3017.	3.6	35
75	Genetic Immunization of Wild-Type and Hepatitis C Virus Transgenic Mice Reveals a Hierarchy of Cellular Immune Response and Tolerance Induction against Hepatitis C Virus Structural Proteins. <i>Journal of Virology</i> , 2001, 75, 12121-12127.	1.5	30
76	Novel Cell-Based Hepatitis C Virus Infection Assay for Quantitative High-Throughput Screening of Anti-Hepatitis C Virus Compounds. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 995-1004.	1.4	30
77	Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 841-853.	2.9	30
78	Monoclonal Antibodies with Broad Specificity for Hepatitis C Virus Hypervariable Region 1 Variants Can Recognize Viral Particles. <i>Journal of Immunology</i> , 2001, 167, 3878-3886.	0.4	29
79	Ribavirin improves the IFN- λ 3 response of natural killer cells to IFN-based therapy of hepatitis C virus infection. <i>Hepatology</i> , 2014, 60, 1160-1169.	3.6	26
80	Rhesus iPSC Safe Harbor Gene-Editing Platform for Stable Expression of Transgenes in Differentiated Cells of All Germ Layers. <i>Molecular Therapy</i> , 2017, 25, 44-53.	3.7	26
81	N-Myc Downstream-Regulated Gene 1 Restricts Hepatitis C Virus Propagation by Regulating Lipid Droplet Biogenesis and Viral Assembly. <i>Journal of Virology</i> , 2018, 92, .	1.5	24
82	High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors. <i>ACS Combinatorial Science</i> , 2015, 17, 641-652.	3.8	23
83	Controlled Human Infection Model "Fast Track to HCV Vaccine?". <i>New England Journal of Medicine</i> , 2021, 385, 1235-1240.	13.9	22
84	In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis. <i>Hepatology</i> , 2011, 54, 425-433.	3.6	21
85	MicroRNA-135a Modulates Hepatitis C Virus Genome Replication through Downregulation of Host Antiviral Factors. <i>Virologica Sinica</i> , 2019, 34, 197-210.	1.2	19
86	Evaluation of antiviral drug synergy in an infectious HCV system. <i>Antiviral Therapy</i> , 2016, 21, 595-603.	0.6	18
87	Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1. <i>Cell Chemical Biology</i> , 2020, 27, 780-792.e5.	2.5	18
88	N-Terminal PreS1 Sequence Regulates Efficient Infection of Cell-Culture-Generated Hepatitis B Virus. <i>Hepatology</i> , 2021, 73, 520-532.	3.6	17
89	Discovery of Small Molecule Entry Inhibitors Targeting the Fusion Peptide of SARS-CoV-2 Spike Protein. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1267-1274.	1.3	16
90	Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6364-6383.	2.9	12

#	ARTICLE	IF	CITATIONS
91	Hepatitis C Virus Infection Induces Hepatic Expression of NF- κ B-Inducing Kinase and Lipogenesis by Downregulating miR-122. <i>MBio</i> , 2019, 10, .	1.8	12
92	Hepatitis B virus “ recent therapeutic advances and challenges to cure. <i>Journal of Hepatology</i> , 2020, 73, 694-695.	1.8	12
93	Infection courses, virological features and IFN- γ responses of HBV genotypes in cell culture and animal models. <i>Journal of Hepatology</i> , 2021, 75, 1335-1345.	1.8	12
94	Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2018, 217, 1761-1769.	1.9	11
95	TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes. <i>Gastroenterology</i> , 2018, 155, 1923-1935.e8.	0.6	11
96	Genetically edited hepatic cells expressing the NTCP-S267F variant are resistant to hepatitis B virus infection. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 597-605.	1.8	11
97	Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors. <i>MBio</i> , 2022, 13, e0323821.	1.8	11
98	Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion. <i>Nature Microbiology</i> , 2020, 5, 1532-1541.	5.9	10
99	Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. <i>Antiviral Research</i> , 2015, 124, 20-29.	1.9	9
100	A dual conditional CRISPR-Cas9 system to activate gene editing and reduce off-target effects in human stem cells. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 656-669.	2.3	9
101	Single Strain Isolation Method for Cell Culture-Adapted Hepatitis C Virus by End-Point Dilution and Infection. <i>PLoS ONE</i> , 2014, 9, e98168.	1.1	7
102	A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. <i>Antiviral Research</i> , 2019, 163, 149-155.	1.9	6
103	Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle. <i>Antiviral Therapy</i> , 2019, 24, 371-381.	0.6	5
104	Hepatitis B: a new weapon against an old enemy. <i>Nature Medicine</i> , 2021, 27, 1672-1673.	15.2	5
105	Metabolic Profiling Reveals Aggravated Non-Alcoholic Steatohepatitis in High-Fat High-Cholesterol Diet-Fed Apolipoprotein E-Deficient Mice Lacking Ron Receptor Signaling. <i>Metabolites</i> , 2020, 10, 326.	1.3	3
106	Border Control in Hepatitis C Virus Infection: Inhibiting Viral Entry. <i>ACS Infectious Diseases</i> , 2015, 1, 416-419.	1.8	2
107	Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus Assembly. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9431-9443.	2.9	2
108	Coronavirus Disease-19 Has Come Home to Roost in Gastroenterology. <i>Gastroenterology</i> , 2020, 159, 36-38.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Stem cell-derived HCV infection systems illustrate the bright future of human hepatocyte research. Gut, 2020, 69, 1550-1551.	6.1	0